Generation of Pichia protein expression strains for commercial protein production
With over 15 years of experience in Pichia strain development, and implementation of our cutting-edge UNLOCK PICHIA® technology platform, we offer an unparalleled combination of know-how and technology to fast-track your protein expression project. By combining rational strain design with process optimization, VALIDOGEN transforms Pichia pastoris into a precision tool for recombinant protein production.
Effective process development starts with the targeted and time-saving generation of high-productivity strains, taking into account your economic target values and regulatory requirements from an early stage. The UNLOCK PICHIA® technology platform comprises a large number of versatile expression tools for the generation of effective industrial Pichia protein production strains without compromising development timelines.
VALIDOGEN’s UNLOCK PICHIA® platform boosts the methanol-induced or methanol-free expression of your protein by comparing thousands of combinations of different promoter variants, strain backgrounds, helper factors, and secretion signals. Our unparalleled spectrum of expression tools and ingenious expression strategies function together to generate high-performance Pichia strains and improve protein quality. We rapidly identify Pichia production strains secreting your protein with highest product yields by applying a combinatorial microscale cultivation & screening regime.
All aspects of manufacturability from targeted debottlenecking to product quality (including glycosylation issues) and regulatory requirements (antibiotic-free strain selection), as well as process safety (methanol-free production) and process economy are considered and integrated at the earliest possible stage during Pichia strain/cell line development. We then further unlock Pichia's potential by applying robust and highly proven cultivation protocols through VALIDOGEN's expert process development and optimization program.
We harness our exclusive Pichia pastoris engineering platform to create robust, high-performing production strains designed to meet commercial manufacturing requirements. This advanced toolbox includes a proprietary library of strong and tunable promoters (methanol-induced and methanol-free), synthetic secretion signals, co-expression helper factors, and host strains that collectively drive exceptional expression performance.
With over 15 years of dedicated Pichia R&D, our team has unmatched expertise in yeast strain development. We combine cutting-edge science with experience-driven insights, ensuring your project benefits from both advanced technology and skilled Pichia specialists.
Get boosted protein yields with our optimized strains while maintaining product quality. Higher titers translate to lower production costs and more efficient manufacturing, giving you a cost-effective path to scale.
By leveraging our broad range of UNLOCK PICHIA® platform tools we deliver strains targeted to your protein expression needs. High-throughput screening allows us to identify top performing clones in an efficient timeframe, streamlining your progression to commercial manufacturing.
We offer highly efficient methanol-induced promoters along with methanol-free variants and protocols, allowing you to choose the expression system that best suits your product and regulatory environment.
For applications such as food and feed, where there may be regulatory constraints, we can provide platform strains completely free of antibiotic resistance markers (ARMs-free).
Our UNLOCK PICHIA® strain development program is executed with Chemistry, Manufacturing and Controls (CMC) requirements in mind. From the earliest stage, we optimize for robustness, consistency, and scalability. The result is a strain and process suited for GMP manufacturing, de-risking your move towards clinical or commercial production.
Strains we deliver are supported with full documentation of genetic constructs and development history, streamlining your regulatory submissions.
We harness our exclusive Pichia pastoris engineering platform to create robust, high-performing production strains designed to meet commercial manufacturing requirements. This advanced toolbox includes a proprietary library of strong and tunable promoters (methanol-induced and methanol-free), synthetic secretion signals, co-expression helper factors, and host strains that collectively drive exceptional expression performance.
With over 15 years of dedicated Pichia R&D, our team has unmatched expertise in yeast strain development. We combine cutting-edge science with experience-driven insights, ensuring your project benefits from both advanced technology and skilled Pichia specialists.
Get boosted protein yields with our optimized strains while maintaining product quality. Higher titers translate to lower production costs and more efficient manufacturing, giving you a cost-effective path to scale.
By leveraging our broad range of UNLOCK PICHIA® platform tools we deliver strains targeted to your protein expression needs. High-throughput screening allows us to identify top performing clones in an efficient timeframe, streamlining your progression to commercial manufacturing.
We offer highly efficient methanol-induced promoters along with methanol-free variants and protocols, allowing you to choose the expression system that best suits your product and regulatory environment.
For applications such as food and feed, where there may be regulatory constraints, we can provide platform strains completely free of antibiotic resistance markers (ARMs-free).
Our UNLOCK PICHIA® strain development program is executed with Chemistry, Manufacturing and Controls (CMC) requirements in mind. From the earliest stage, we optimize for robustness, consistency, and scalability. The result is a strain and process suited for GMP manufacturing, de-risking your move towards clinical or commercial production.
Strains we deliver are supported with full documentation of genetic constructs and development history, streamlining your regulatory submissions.
Access the full offerings of our UNLOCK PICHIA® toolbox with a fast and reliable extended screening assessing thousands of clones. Let us identify the optimal genetic combination of novel strain, promoter, and secretion signal, and additionally evaluate our helper factor suite to generate a high-performance Pichia cell line ready for scale-up.
Capable of monitoring and controlling temperature, pH value, level of dissolved oxygen, and feed rate, our 1 mL well microscale cultivation device is the perfect step between a shaken screening system and a bioreactor. Using this system, the performance of different Pichia strains can be assessed using an identical protocol, or the effect of selected upstream process parameters on protein production can be evaluated.
1 L and 10 L bioreactors are used to confirm the productivity levels of top-performing Pichia clones, and to generate material for purification. Our fermentation specialists have developed highly transferable and scalable protocols for both methanol-induced and methanol-free protein production processes.
Our DSP scientists can develop an initial protein purification protocol to provide you with a non-GMP sample in a buffer of your choice. According to your requirements, we will also take downstream processing one step further providing full protein purification process development for a robust scalable process.
We provide high-quality glycerol preparations to ensure the integrity of your Pichia cell line. Cell line characterization includes purity check, viability check, assessment of the integration of expression cassette(s), whole genome sequencing, and copy number determination.
We leverage our expertise and our proprietary UNLOCK PICHIA® toolbox of promoters, secretion signals, co-expression helper factors, and platform strains. By generating extensive genetic diversity and systematically screening for high-performing strains, we can identify optimal expression solutions for each individual protein.
Methanol-free Pichia pastoris strains are specifically engineered to achieve high-level protein expression without the need for methanol induction. The benefits include:
The choice depends on your protein, its intended application, or production site. For food, feed, or similar applications, methanol-free strains may be required.
In other cases, we recommend evaluating both methanol-induced and methanol-free systems, since performance can vary depending on the specific protein. Our team can design comparative development strategies to identify the best-performing option for your project.
Timelines vary depending on project scope and complexity:
VALIDOGEN combines proprietary secretion signals with helper-factor co-expression to improve recombinant protein secretion in Pichia pastoris. Our secretion signals can outperform the conventional α-MF signal, while selected helper factors support protein folding and processing. This enables target-specific optimization of secretion efficiency and productivity.
VALIDOGEN applies a systematic screening approach as part of its Expression Feasibility Studies. Multiple secretion signals are evaluated in parallel together with other critical expression parameters, enabling data-driven selection of the most effective secretion strategy for each target protein.
Yes. VALIDOGEN develops recombinant Pichia pastoris production strains using antibiotic-free selection strategies, including auxotrophic selection systems. ARMs-free strain development is particularly advantageous for applications in food, feed, industrial biotechnology and other sectors, where regulatory requirements, product safety considerations and consumer acceptance may favor production strains without antibiotic resistance markers.
Yes. Codon optimization is generally performed at the beginning of the project and serves as the basis for synthetic gene synthesis and subsequent expression studies.
Deletion of the AOX1 gene results in Pichia pastoris strains with a MutS (methanol utilization slow) phenotype. Since these strains rely on AOX2 only for the first step of methanol metabolism, they exhibit reduced methanol utilization compared to Mut+ strains. In methanol-induced fermentation, this reduces oxygen demand and heat generation while enabling more controlled methanol consumption and induction. VALIDOGEN’s UNLOCK PICHIA® platform strains are based on the MutS phenotype, providing a robust basis for efficient methanol-induced recombinant protein production. VALIDOGEN’s methanol-free UNLOCK PICHIA® technology however takes this one giant step further, and eliminates methanol entirely, simplifying process handling and supporting safer large-scale manufacturing.
Yes. Multi-copy integration can be applied during Pichia pastoris strain development to generate strains containing multiple copies of the gene of interest. However, high gene copy numbers are not always required to achieve strong expression. VALIDOGEN’s exclusive promoter toolbox can deliver high transcriptional activity without the need to substantially increase copy number. Therefore, VALIDOGEN typically develops low- to medium-copy strains, which can help maintain genetic stability while still achieving high recombinant protein productivity.
No. A higher gene copy number does not necessarily result in higher recombinant protein productivity. While multi-copy strains can increase transcription of the target gene, very high transcript levels may overload cellular processes involved in translation, protein folding, and protein secretion. This can lead to reduced growth, intracellular accumulation, product degradation or decreased secretion efficiency.
For this reason, VALIDOGEN uses screening and experimental characterization to identify the optimal balance between gene copy number, expression strength and cellular production capacity. The objective is not simply to maximize the number of gene copies integrated, but to develop a robust production strain with high product yield and quality.
Contact our Pichia pastoris experts to discuss your strain development project and find the right solution. Send any project related request to project@validogen.com, directly to our scientists, or use our contact form.
